These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33557518)

  • 1. Allosteric Inhibition of the Epidermal Growth Factor Receptor.
    Sinclair JKL; Robertson WE; Mozumdar D; Quach K; Schepartz A
    Biochemistry; 2021 Feb; 60(7):500-512. PubMed ID: 33557518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of macrocyclization on allosteric, juxtamembrane-derived, stapled peptide inhibitors of the epidermal growth factor receptor (EGFR).
    Sinclair JK; Schepartz A
    Org Lett; 2014 Sep; 16(18):4916-9. PubMed ID: 25207804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors.
    Lowder MA; Doerner AE; Schepartz A
    J Am Chem Soc; 2015 May; 137(20):6456-9. PubMed ID: 25973741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation.
    Thiel KW; Carpenter G
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19238-43. PubMed ID: 18042729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
    Wang A; Li X; Wu H; Zou F; Yan XE; Chen C; Hu C; Yu K; Wang W; Zhao P; Wu J; Qi Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
    J Med Chem; 2017 Apr; 60(7):2944-2962. PubMed ID: 28282122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
    J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.
    Hao Y; Lyu J; Qu R; Sun D; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
    Sci Rep; 2017 Jun; 7(1):3830. PubMed ID: 28630494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
    Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
    Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
    Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain.
    Mozumdar D; Doerner A; Zhang JY; Rafizadeh DN; Schepartz A
    Biochemistry; 2020 Oct; 59(41):3965-3972. PubMed ID: 32941004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural determinants for membrane binding of the EGFR juxtamembrane domain.
    Wu Z; Li L; Zhu L; Wang R; Dong Y; Zhang Y; Wang Y; Wang J; Zhu L
    FEBS Lett; 2024 Jun; 598(11):1402-1410. PubMed ID: 38589226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Allosteric Coupling into and through the Plasma Membrane by EGFR.
    Sinclair JKL; Walker AS; Doerner AE; Schepartz A
    Cell Chem Biol; 2018 Jul; 25(7):857-870.e7. PubMed ID: 29731426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting epidermal growth factor receptor at a distance.
    Sinclair JK; Denton EV; Schepartz A
    J Am Chem Soc; 2014 Aug; 136(32):11232-5. PubMed ID: 25075632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
    Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
    Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of the EGFR juxtamembrane domain with PIP2-containing lipid bilayers: Insights from multiscale molecular dynamics simulations.
    Abd Halim KB; Koldsø H; Sansom MSP
    Biochim Biophys Acta; 2015 May; 1850(5):1017-1025. PubMed ID: 25219456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between the juxtamembrane domain of the EGFR and calmodulin measured by surface plasmon resonance.
    Aifa S; Johansen K; Nilsson UK; Liedberg B; Lundström I; Svensson SP
    Cell Signal; 2002 Dec; 14(12):1005-13. PubMed ID: 12359306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.